Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-κB pathways.

Su, Shao-Hua

Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-κB pathways. [electronic resource] - Naunyn-Schmiedeberg's archives of pharmacology Dec 2017 - 1189-1200 p. digital

Publication Type: Journal Article

1432-1912

10.1007/s00210-017-1417-9 doi


Amidohydrolases--antagonists & inhibitors
Animals
Anti-Inflammatory Agents--pharmacology
Benzamides--pharmacology
Benzoxazines--pharmacology
Cannabinoid Receptor Agonists--pharmacology
Carbamates--pharmacology
Cerebrovascular Disorders--drug therapy
Endocannabinoids--physiology
Hippocampus--drug effects
Macrophage Activation--drug effects
Male
Morpholines--pharmacology
NF-kappa B--antagonists & inhibitors
Naphthalenes--pharmacology
Neuritis--drug therapy
Prefrontal Cortex--drug effects
Rats
Rats, Sprague-Dawley
Signal Transduction--drug effects
Transcription Factor RelA--drug effects